$HRMY Cashflow Statement | Understand Stock

$HRMY

$37.95 +$1.12 (3.04%) Close

$HRMY Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net income
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and impairment of long-lived assets
Intangible amortization
Acquired in-process research & development (IPR&D) expense
Epygenix Acquisition
Total acquired in-process research & development (IPR&D) expense
Stock-based compensation
Stock appreciation rights market adjustment
Debt issuance costs amortization
Deferred taxes
Amortization of premiums and accretion of discounts on Investment securities
Loss on debt extinguishment
Other non-cash expenses
Change in operating assets and liabilities:
Trade receivables
Inventory
Prepaid expenses and other assets
Other non-current assets
Trade payables
Accrued expenses and other current liabilities
Other non-current liabilities
Other liabilities

Net cash provided by operating activities
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investment securities
Proceeds from maturities and sales of investment securities
Purchase of property and equipment
Acquisition of Zynerba Pharmaceuticals, Inc., net of cash acquired
Payment of license fee and milestone
Payment of milestones
Payment of upfront fee related to license agreements
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock
Common stock issuance costs
Proceeds from long-term debt
Debt issuance costs
Extinguishment of debt
Extinguishment of debt exit fees
Principal repayment of long-term debt
Repurchase of common stock
Payments of employee withholding taxes related to stock-based awards
Proceeds from exercised options
Net cash used in financing activities

NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-Beginning of period
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH-End of period
Supplemental Disclosure of Cash Flow Information:
Cash paid during the year for interest
Cash paid during the year for income taxes net of refunds received

Comments